
864

## References

7. Patel AM, Goldfarb S. Got calcium? Welcome to the calcium-alkali syndrome. J Am Soc Nephrol 2010; 21:1440-3. http://jasn.asnjournals.org/content/21/9/1440.long
8. Berenson JR. Treatment of hypercalcemia of malignancy with bisphosphonates. Semin Oncol 2002; 29(6 Suppl 21):12-18. https://www.ncbi.nlm.nih.gov/pubmed/12584690
9. LeGrand SB, Leskuski D, Zama I. Narrative review: furosemide for hypercalcemia: an unproven yet common practice. Ann Intern Med 2008; 149:259-63. https://www.ncbi.nlm.nih.gov/pubmed/18711156
10. Robey RB, Lash JP, Arruda JA. Does furosemide have a role in the management of hypercalcemia? Ann Intern Med 2009; 150:146-7. https://www.ncbi.nlm.nih.gov/pubmed/19153420
11. Fitzpatrick LA. The hypocalcemic states. In: Favus M (ed) Disorders of bone and mineral metabolism. Philadelphia, PA: Lippincott Williams & Wilkins, 2002:568-88
12. Kramer HJ, Choi HK, Atkinson K, et al. The association between gout and nephrolithiasis in men: The Health Professionals' Follow-Up Study. Kidney Int 2003; 64:1022-6. https://www.ncbi.nlm.nih.gov/pubmed/12911552
13. Kanis JA, Johnell O, Oden A, et al. FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int 2008; 19:385-97. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2267485/
14. NICE. Alendronate, etidronate, risedronate, raloxifene and strontium ranelate for the primary prevention of osteoporotic fragility fractures in postmenopausal women [TA160]. 2008, updated 2011. https://www.nice.org.uk/Guidance/ta160
15. Howe TE, Shea B, Dawson LJ, et al. Exercise for preventing and treating osteoporosis in postmenopausal women. Cochrane Database Syst Rev 2011; 7:CD000333. http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD000333.pub2/abstract
16. Gillespie WJ. Hip protectors for preventing hip fractures in older people. Cochrane Database Syst Rev 2010; 10:CD001255. http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD001255.pub4/abstract
17. Eberling P. Osteoporosis in men. N Engl J Med 2008; 358:1474-82. http://www.nejm.org/doi/full/10.1056/NEJMcp0707217
18. Vollbrecht J, Rao DS. Tumor-induced osteomalacia. N Engl J Med 2008; 358:1282. http://www.nejm.org/doi/full/10.1056/NEJMicm066066#t=article
19. Wermers RA, Tiegs RD, Atkinson EJ, et al. Morbidity and mortality associated with Paget's disease of bone: a population study. J Bone Miner Res 2008; 23:819-25. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2515478/
20. NICE. Chronic kidney disease: Early identification and management of chronic kidney disease in adults in primary and secondary care [CG73]. 2008. https://www.nice.org.uk/guidance/cg73
21. Anon. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344:1383-9. https://www.ncbi.nlm.nih.gov/pubmed/7968073
22. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995; 333:1301-8. http://www.nejm.org/doi/full/10.1056/NEJM199511163332001#t=article
23. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996; 335:1001-9. http://www.nejm.org/doi/full/10.1056/NEJM199610033351401#t=article
24. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360:7-22. http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(02)09327-3/abstract
25. Libby P. Inflammation in atherosclerosis. Nature 2002; 420:868-74. http://www.nature.com/nature/journal/v420/n6917/full/nature01323.html
26. Versmissen J, Oosterveer DM, Yazdanpanah M, et al. Efficacy of statins in familial hypercholesterolaemia: a long term cohort study. BMJ 2008; 337:a2423 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2583391/
27. NICE. Cardiovascular disease: Risk assessment and reduction, including lipid modification [CG181]. 2014, updated 2016. https://www.nice.org.uk/guidance/CG181
28. McKenney JM, Davidson MH, Jacobson TA, et al. Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force. Am J Cardiol 2006; 8A:89C-94C. https://www.ncbi.nlm.nih.gov/pubmed/16581336
29. Robinson JG, Farnier M, Krempf M, et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med 2015; 372(16):1489-99. http://www.nejm.org/doi/full/10.1056/NEJMoa1501031

## Chapter 15: Eponymous syndromes

1. Todd J. The syndrome of Alice in Wonderland. Can Med Assoc J 1955; 73(9):701-4. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1826192/
2. Cau C. The Alice in Wonderland syndrome. Minerva Med 1999; 90(10):397-401. https://www.ncbi.nlm.nih.gov/pubmed/10767914
3. Fritschy D, Fasel J, Imbert JC, et al. The popliteal cyst. Knee Surg Sports Traumatol Arthrosc 2006; 14(7):623-8. https://www.ncbi.nlm.nih.gov/pubmed/16362357
4. Scheinfeld NS. Erythema induratum (nodular vasculitis). Medscape. 2016. http://emedicine.medscape.com/article/1083213-overview
5. Hakim A, Gavin Clunie G, Haq I. Beh√ßet's disease. In: Oxford Handbook of Clinical Rheumatology (3rd edn). Oxford: Oxford University Press, 2011:490-1.
6. Mariotti AJ, Agrawal R, Hotaling AJ. The role of tonsillectomy in pediatric IgA nephropathy. Arch Otolaryngol Head Neck Surg 2009; 135(1):85-7. https://www.ncbi.nlm.nih.gov/pubmed/19153312
7. Fourcade G, Bengler C, Campello CH, et al. [Bickerstaff's syndrome presenting with coma, tetraplegia and blindness]. Rev Neurol (Paris) 2007; 163(2):231-4. https://www.ncbi.nlm.nih.gov/pubmed/17351542
8. Fitzgerald RC, di Pietro M, Ragunath K, et al. British Society of Gastroenterology guidelines on the diagnosis and management of Barrett's oesophagus. Gut 2014; 63(1):7-42. http://gut.bmj.com/content/63/1/7.long
9. Tham T. Guidelines on the diagnosis and management of Barrett's oesophagus - an update 2015. [Online only] http://www.bsg.org.uk/clinical-guidelines/oesophageal/guidelines-on-the-diagnosis-and-management-of-barrett-s-oesophagus.html